CDH3 and cancer: After confirming the long‐term knockdown of CDH3/P‐cadherin (Fig. S4A,B), this shRNA‐based GBML18 model was validated in vitro for key cancer hallmarks, globally recapitulating the association of P‐cadherin silencing with compromised GBM cell viability (Fig. S4C,D) and migration capacity (Fig. S4E,F).